The global pharmaceutical CDMO market size accounted for USD 184.90 billion in 2024, grew to USD 197.4 billion in 2025 and is projected to surpass around USD 368.70 billion by 2034, representing a healthy CAGR of 7.2% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Pharmaceutical CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Pharmaceutical CDMO Market, by Service Type, 2024-2034
8.1.1. Active Pharmaceutical Ingredient (API) Manufacturing
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Liquid Dose Formulation
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Injectable Dose Formulation
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Secondary Packaging
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Pharmaceutical CDMO Market, by Research Phase, 2024-2034
9.1.1. Pre-clinical
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Phase I
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Phase II
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Phase III
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Phase IV
9.1.5.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.1.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.2.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.3.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.4.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.5.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Research Phase (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Service Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Research Phase (2021-2034)
11.1. Bushu Pharmaceuticals Ltd.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Nipro Corporation
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Thermo Fisher Scientific Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Samsung Biologics
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Laboratory Corporation of America Holdings
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Siegfried Holding Ag
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Catalent, Inc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Lonza Group AG
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Recipharm Ab
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Piramal Pharma Solutions
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample